ATE132040T1 - Verwendung von phospholipiden zur herstellung eines topischen arzneimittels zur beinflussung des serumcholesterinspiegels - Google Patents

Verwendung von phospholipiden zur herstellung eines topischen arzneimittels zur beinflussung des serumcholesterinspiegels

Info

Publication number
ATE132040T1
ATE132040T1 AT91915084T AT91915084T ATE132040T1 AT E132040 T1 ATE132040 T1 AT E132040T1 AT 91915084 T AT91915084 T AT 91915084T AT 91915084 T AT91915084 T AT 91915084T AT E132040 T1 ATE132040 T1 AT E132040T1
Authority
AT
Austria
Prior art keywords
cholesterol levels
serum cholesterol
phospholipids
production
topical drug
Prior art date
Application number
AT91915084T
Other languages
English (en)
Inventor
Sung Lan Hsia
Jin Lin He
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Application granted granted Critical
Publication of ATE132040T1 publication Critical patent/ATE132040T1/de
Priority claimed from PCT/US1996/001117 external-priority patent/WO1997028806A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT91915084T 1990-07-30 1991-07-30 Verwendung von phospholipiden zur herstellung eines topischen arzneimittels zur beinflussung des serumcholesterinspiegels ATE132040T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/559,932 US5231090A (en) 1990-07-30 1990-07-30 Treatment for hypercholesterolemia
PCT/US1996/001117 WO1997028806A1 (en) 1993-04-23 1996-02-12 Treatment for hypercholesterolemia

Publications (1)

Publication Number Publication Date
ATE132040T1 true ATE132040T1 (de) 1996-01-15

Family

ID=26790867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915084T ATE132040T1 (de) 1990-07-30 1991-07-30 Verwendung von phospholipiden zur herstellung eines topischen arzneimittels zur beinflussung des serumcholesterinspiegels

Country Status (11)

Country Link
US (1) US5231090A (de)
EP (1) EP0542864B1 (de)
JP (1) JP3061415B2 (de)
AT (1) ATE132040T1 (de)
AU (1) AU648482B2 (de)
CA (1) CA2088254C (de)
DE (1) DE69115909T2 (de)
DK (1) DK0542864T3 (de)
ES (1) ES2081488T3 (de)
GR (1) GR3018889T3 (de)
WO (1) WO1992002226A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498607A (en) * 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
TW252918B (de) * 1993-03-31 1995-08-01 Senju Pharma Co
US6773719B2 (en) 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US5746223A (en) 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US6312719B1 (en) 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6139871A (en) * 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5656284A (en) * 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
US5709878A (en) * 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
GB0004686D0 (en) * 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
US7250304B2 (en) * 2000-03-31 2007-07-31 The Regents Of The University Of California Functional assay of high-density lipoprotein
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
EP1320371A2 (de) * 2000-07-31 2003-06-25 Ottawa Heart Institute Research Corporation Geladene phospholipid enthaltende zusammensetzungen und verfahren zu ihrer verwendung
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
CN1635873A (zh) * 2001-09-28 2005-07-06 埃斯佩里安医疗公司 在高压下挤出泡囊的方法和装置
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
WO2004064820A2 (en) * 2003-01-20 2004-08-05 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US20080207503A1 (en) * 2005-06-22 2008-08-28 Chung Byung-Hong Composition and Treatment Methods for Coronary Artery Disease
DE102007051339A1 (de) * 2007-10-26 2009-04-30 Müller-Enoch, Dieter, Prof. Dr. Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien
ITPD20100130A1 (it) * 2010-04-28 2011-10-29 Antonio Gambino Prodotto anti ipercolesterolemico

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3203862A (en) * 1960-03-11 1965-08-31 Jones John Harris Oral anti-hypercholesterol composition
US3197371A (en) * 1962-07-06 1965-07-27 Armour Pharma Process for treating hypercholesteralemia
JPS55115820A (en) * 1979-02-27 1980-09-06 Nippon Shoji Kk High-purity phospholipid capsule preparation
JPS5838215A (ja) * 1981-09-01 1983-03-05 Shigeru Tokiwa コレステロールの低下剤
SU1183118A1 (ru) * 1983-10-26 1985-10-07 2-Й Московский Ордена Ленина Государственный Медицинский Институт Им.Н.И.Пирогова Способ получени экстрагента холестерина
JPS6097916A (ja) * 1983-11-01 1985-05-31 Ajinomoto Co Inc コレステロ−ル低下又は上昇抑制作用を有する組成物
JPS60214864A (ja) * 1984-04-09 1985-10-28 Hohnen Oil Co Ltd 栄養補助食品
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
AU594066B2 (en) * 1985-07-26 1990-03-01 Yeda Research And Development Co. Ltd. A special lipid mixture for membrane fluidization
DE4018767A1 (de) * 1990-06-12 1991-12-19 Braun Melsungen Ag Wirkstofffreie liposomen zur behandlung von atherosklerose
EP0582061A1 (de) * 1992-06-17 1994-02-09 Siemens Aktiengesellschaft Kohärent optische Vielkanalanordnung

Also Published As

Publication number Publication date
JPH06501245A (ja) 1994-02-10
EP0542864B1 (de) 1995-12-27
DK0542864T3 (da) 1996-05-13
ES2081488T3 (es) 1996-03-16
AU8428491A (en) 1992-03-02
DE69115909D1 (de) 1996-02-08
GR3018889T3 (en) 1996-05-31
US5231090A (en) 1993-07-27
CA2088254A1 (en) 1992-01-31
EP0542864A4 (en) 1993-06-30
CA2088254C (en) 2003-05-20
DE69115909T2 (de) 1996-05-23
AU648482B2 (en) 1994-04-21
JP3061415B2 (ja) 2000-07-10
WO1992002226A1 (en) 1992-02-20
EP0542864A1 (de) 1993-05-26

Similar Documents

Publication Publication Date Title
ATE132040T1 (de) Verwendung von phospholipiden zur herstellung eines topischen arzneimittels zur beinflussung des serumcholesterinspiegels
EP0336880A3 (de) Verwendung von topisch applizierbaren Präparaten zur Behandlung der Altershaut
FI971420A (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
DE3852116T2 (de) Herstellung von Proteinen in aktiver Form.
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
ATE324884T1 (de) Verwendung von gamma-linolensäure oder dihomogammalinolensäure zur herstellung eines medikaments zur behandlung von huntington's chorea
DE3873800T2 (de) Zusammensetzungen zur behandlung von hypercholesterinaemie.
PT865294E (pt) Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob
DE68905610T2 (de) Verfahren zur Herstellung von Reflexionshologrammen in photopolymerisierbaren Schichten.
ATE280496T1 (de) Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin
DE69029100D1 (de) Verwendung von Ketoconazol und ein Retinoid zur Behandlung der Akne vulgaris
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
ATE151948T1 (de) Hefeformulierung zur herstellung von backwaren
AU2431984A (en) Shampoo Composition of Neostigmine or Pyridostigmine
SE8703115D0 (sv) Forfarande for framstellning av en skida
ATE310525T1 (de) Verwendung von sulfatiden zur behandlung von diabetes
ATE58831T1 (de) Verwendung von dicarbonsaeuren mit 7-13 kohlenstoffatomen oder physiologisch vertraeglichen salzen davon zur herstellung eines arzneimittels zur topischen behandlung von rosazea.
BG100752U (en) Food additive
MX9605753A (es) Aplicacion de alfahidroxidos en estrias distensas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee